BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32803457)

  • 1. Role of Immunotherapy in Advanced Gastroesophageal Cancer.
    Terrero G; Lockhart AC
    Curr Oncol Rep; 2020 Aug; 22(11):112. PubMed ID: 32803457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
    Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
    Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
    Park R; Williamson S; Kasi A; Saeed A
    Anticancer Res; 2018 Oct; 38(10):5569-5580. PubMed ID: 30275174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A good start of immunotherapy in esophageal cancer.
    Zhao Q; Yu J; Meng X
    Cancer Med; 2019 Aug; 8(10):4519-4526. PubMed ID: 31231980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
    Zayac A; Almhanna K
    Transl Gastroenterol Hepatol; 2020; 5():9. PubMed ID: 32190777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in advanced gastric cancer, is it the future?
    Coutzac C; Pernot S; Chaput N; Zaanan A
    Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targetting esophageal and gastric cancers with monoclonal antibodies.
    Norguet E; Dahan L; Seitz JF
    Curr Top Med Chem; 2012; 12(15):1678-82. PubMed ID: 22978338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of gastric cancer: Past, future perspective and challenges.
    Xie J; Fu L; Jin L
    Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
    Alsina M; Moehler M; Lorenzen S
    Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for gastrointestinal malignancies.
    Toomey PG; Vohra NA; Ghansah T; Sarnaik AA; Pilon-Thomas SA
    Cancer Control; 2013 Jan; 20(1):32-42. PubMed ID: 23302905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.
    Cetin B; Wabl CA; Gumusay O
    Immunotherapy; 2023 Aug; 15(12):945-962. PubMed ID: 37291863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
    Li N; Sohal D
    Cancer Immunol Immunother; 2023 Dec; 72(12):3939-3952. PubMed ID: 37995002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progression of immunotherapy in gastric cancer].
    Wei X; Xu R
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expanding role of immunotherapy.
    Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
    Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.